Recombinant Human CRACC/SLAMF7 Fc Chimera Protein, CF Summary
Accession # Q9NQ25
CF stands for Carrier Free (CF). We typically add Bovine Serum Albumin (BSA) as a carrier protein to our recombinant proteins. Adding a carrier protein enhances protein stability, increases shelf-life, and allows the recombinant protein to be stored at a more dilute concentration. The carrier free version does not contain BSA.
In general, we advise purchasing the recombinant protein with BSA for use in cell or tissue culture, or as an ELISA standard. In contrast, the carrier free protein is recommended for applications, in which the presence of BSA could interfere.
|Formulation||Lyophilized from a 0.2 μm filtered solution in PBS.|
|Reconstitution||Reconstitute at 100 μg/mL in PBS.|
|Shipping||The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.|
|Stability & Storage:||Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
Recombinant Human CRACC/SLAMF7 Fc Chimera (Catalog # 1906-SF) inhibits anti-CD3 antibody induced IFN-gamma secretion by human peripheral blood mononuclear cells. The ED50 for this effect is 2-10 μg/mL.
2 μg/lane of Recombinant Human CRACC/SLAMF7 was resolved with SDS-PAGE underreducing (R) and non-reducing (NR) conditions and visualized by Coomassie® Bluestaining, showing bands at 65-75 kDa and 130-150 kDa, respectively.
CD2-like receptor activating cytotoxic cells (CRACC), also known as CS1, novel Ly9, SLAMF7, and CD319, is a 65-75 kDa type I transmembrane glycoprotein in the SLAM subgroup of the CD2 family (1). Mature human CRACC consists of a 204 amino acid (aa) extracellular domain (ECD) with one Ig-like V-set domain and one Ig-like C2-set domain, a 21 aa transmembrane segment, and an 88 aa cytoplasmic domain with one immunoreceptor tyrosine-based switch motif (ITSM) (2, 3). Within the ECD, human CRACC shares 54% and 52% aa sequence identity with mouse and rat CRACC, respectively. There are seven known isoforms of CRACC which are distinguished by deletions and/or substitutions in both their ECD and cytoplasmic domains. CRACC is expressed on the surface of NK cells, CD8+ T cells, activated B cells, and mature dendritic cells (4, 5). Its homophilic interaction induces NK, CTL, and B cell activation (4-7). In human NK cells, activated CRACC transmits signals following association with the adaptor protein EAT-2 (8).
- Veillette, A. (2006) Immunol. Rev. 214:22.
- Tovar, V. et al. (2002) Immunogenetics 54:394.
- Murphy, J.J. et al. (2002) Biochem. J. 361:431.
- Bouchon, A. et al. (2001) J. Immunol. 167:5517.
- Lee, J.K. et al. (2007) J. Immunol. 179:4672.
- Kumaresan, P.R. et al. (2002) Mol. Immunol. 39:1.
- Stark, S. and C. Watzl (2006) Int. Immunol. 18:241.
- Tassi, H. and M. Colonna (2005) J. Immunol. 175:7996.
No product specific FAQs exist for this product, however you mayView all Proteins and Enzyme FAQs
Reviews for Recombinant Human CRACC/SLAMF7 Fc Chimera Protein, CF
There are currently no reviews for this product. Be the first to review Recombinant Human CRACC/SLAMF7 Fc Chimera Protein, CF and earn rewards!
Have you used Recombinant Human CRACC/SLAMF7 Fc Chimera Protein, CF?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image